First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors

A first-in-human study was performed with MP0250, a DARPin drug candidate. MP0250 specifically inhibits both vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) with the aim of disrupting the tumor microenvironment. PATIENTS AND METHODS: A multicenter, open-label, repeated-d...

Descripción completa

Detalles Bibliográficos
Autores principales: Baird, Richard D., Linossi, Constanza, Middleton, Mark, Lord, Simon, Harris, Adrian, Rodón, Jordi, Zitt, Christof, Fiedler, Ulrike, Dawson, Keith M., Leupin, Nicolas, Stumpp, Michael T., Harstrick, Andreas, Azaro, Analía, Fischer, Stefanie, Omlin, Aurelius
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8196087/
https://www.ncbi.nlm.nih.gov/pubmed/33301375
http://dx.doi.org/10.1200/JCO.20.00596

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8196087/
https://www.ncbi.nlm.nih.gov/pubmed/33301375
http://dx.doi.org/10.1200/JCO.20.00596

Ejemplares similares